Revolution Medicine's experimental pancreatic cancer drug daraxonrasib has shown remarkable results by doubling survival time compared to standard chemotherapy. According to multiple reports from Reuters, The Guardian, Sky News, CBS News, PBS, Daily Mail and StatNews the once-daily pill significantly improved symptoms and extended lives of patients who had previously failed one round of chemotherapy.
Key Takeaways
Revolution Medicine's experimental pancreatic cancer drug daraxonrasib has shown remarkable results in doubling survival time compared to standard chemotherapy.
- Daraxonrasib reduced overall risk of death by 60% and halted tumor progression in nearly a third of patients.
- The trial involved 500 patients across North America, Europe, and Asia.
- Patients taking daraxonrasib lived for an average of 13.2 months compared to 6.7 months with chemotherapy.
- Common side effects included rash, inflammation in the mouth, nausea, and diarrhea but were manageable.
⚖
▼Source Claims Check
High ConsensusAll 8 publishers report consistent facts across 3 key claims.
| Claim | Status | Reason | |
|---|---|---|---|
| Survival Time | Broad Agreement | 13.2 months for daraxonrasib vs. 6.7 months for chemotherapy | |
| Risk Of Death Reduction | Broad Agreement | Daraxonrasib reduced overall risk of death by 60% | |
| Tumor Progression Halt/reversal | Broad Agreement | Nearly a third of patients on daraxonrasib saw tumor regression vs. just 10% in chemotherapy group |
Survival Time
Broad Agreement13.2 months for daraxonrasib vs. 6.7 months for chemotherapy
Risk Of Death Reduction
Broad AgreementDaraxonrasib reduced overall risk of death by 60%
Tumor Progression Halt/reversal
Broad AgreementNearly a third of patients on daraxonrasib saw tumor regression vs. just 10% in chemotherapy group
This analysis is AI-generated and may not perfectly represent each source's reporting. Always read the original articles for full context.
The clinical trial involving 500 patients demonstrated that daraxonrasib reduced overall risk of death by 60% compared to those treated with chemotherapy. The drug also halted or reversed tumor progression in nearly a third of patients, compared to just 10% in the chemotherapy group. These findings were presented at the American Society of Clinical Oncology (ASCO) annual meeting and published in the New England Journal of Medicine.
Dr. Rachna Shroff, an ASCO expert in pancreatic cancer from the University of Arizona Cancer Center, described the results as 'revolutionary,' noting that such a doubling of survival time has never been seen in patients whose cancer progressed after chemotherapy. The trial showed that patients taking daraxonrasib lived for an average of 13.2 months compared to 6.7 months for those on standard chemotherapy.
Common side effects included rash, inflammation in the mouth, nausea and diarrhea but these were largely manageable with antibiotics and topical steroids. The FDA has granted expanded access to the drug and plans a speedy review process. Revolution Medicine is already testing daraxonrasib in earlier-stage diseases and in combination with other treatments to further extend survival rates.
How this summary was created
This summary synthesizes reporting from 8 independent publishers using AI. All sources are cited and linked below. NewsBalance is a news aggregator and media literacy tool, not a news publisher. AI-generated content may contain errors or inaccuracies — always verify important information with the original sources.